The chimeric monoclonal anti-CD20 antibody rituximab (Rituxan) has been shown to have clinical activity in patients with
K. E. Summers
Advertisement
Articles by K. E. Summers
Advertisement
Latest Updated Articles
- PCR Analysis for the t(14;18) Translocation in Patients With Recurrent Follicular Lymphoma Following Immunotherapy With Rituximab (IDEC-C2B8)
Published: March 1st 1999 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group
2
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
3
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
4
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
5
